A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Iron Deficiency Anemia

In brief

The primary objective of the study is to evaluate and compare the effect of iron isomaltoside 1000 to placebo in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be used.

Key facts

Study ID

NCT02172001

Run by

Pharmacosmos A/S

People needed

0

Last updated by the study team

2016-09-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women ≥ 18 years having IDA caused by different aetiologies* such as ab-normal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy** for at least one month*** prior to study enrolment
• Hb < 11 g/dL
• TSAT < 20 %
• S-ferritin < 100 ng/mL
• Willingness to participate and signing the informed consent form (ICF)

You may not qualify if…

• Hb < 6 g/dL
• Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreat-ed vitamin B12 or folate deficiency, haemolytic anaemia)
• Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and hae-mosiderosis)
• Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times upper limit of normal)
• Active acute or chronic infections (assessed by clinical judgement supplied with white blood cells (WBC) and C-reactive protein (CRP))
• Body weight < 50 kg
• Pregnant or nursing women. In order to avoid pregnancy, women of childbearing po-tential have to use adequate contraception (e.g. intrauterine devices, hormonal contra-ceptives, or double barrier method) during the whole study period and 7 days after the last dosing
• History of multiple allergies
• Known hypersensitivity to parenteral iron or any excipients in the investigational drug products
• Erythropoietin treatment within 8 weeks prior to the screening visit
• Other intravenous (IV) iron treatment or blood transfusion within 4 weeks prior to the screening visit
• Participation in any other interventional clinical study within 3 months prior to the screening
• Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus

Where it is running

• Study site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.